Results 121 to 130 of about 84,233 (235)

Application and Challenges of Chimeric Antigen Receptor T Cell Therapy in Systemic Rheumatic Diseases and Autoimmune Disorders

MedComm, Volume 7, Issue 4, April 2026.
CAR‐T cell therapy in systemic rheumatic diseases and autoimmune disorders. (This figure was created using BioRender.com.) ABSTRACT Chimeric antigen receptor T (CAR‐T) cell therapy, originally developed for hematologic malignancies, has emerged as a transformative candidate for systemic rheumatic diseases and autoimmune disorders (AIDs).
Zhidan Fan, Li Zhang, Haiguo Yu
wiley   +1 more source

Adult T‐cell leukemia/lymphoma in French Guiana (1990–2019): Epidemiology, clinical features, and HTLV‐1 genetic diversity in the two main ethnic populations

International Journal of Cancer, Volume 158, Issue 6, Page 1528-1540, 15 March 2026.
What's new? Adult T‐cell leukemia/lymphoma (ATL) is a rare and aggressive malignancy caused by human T‐cell leukemia virus type 1 (HTLV‐1). The authors comprehensively analyzed the epidemiological and clinical features of ATL over a 30‐year period in French Guiana, a region with high HTLV‐1 endemicity and a multiethnic population.
Jill‐Léa Ramassamy, Patricia Tortevoye, Balthazar Ntab, Gabriel Carles, Jean‐Pierre Droz, Pierre Couppié, Giovanni Begliomini, Jean‐Francois Carod, N'detodji‐Bill Wankpo, Karim Abdelmoumen, Philippe V. Afonso, Olivier Cassar, Antoine Talarmin, Olivier Hermine, Loïc Epelboin, Ambroise Marçais, Antoine Gessain   +16 more
wiley   +1 more source

Cytokine‐Engineered Chimeric Antigen Receptor‐T Cell Therapy: How to Balance the Efficacy and Toxicity

Advanced Science, Volume 13, Issue 14, 9 March 2026.
Cytokine‐engineered CAR‐T cells represent a promising immunotherapy against malignancies due to direct tumor killing and potent immunity response. However, significant toxicities, including CRS and ICANS, have restricted clinical applications. How to keep the risk‐benefit balance of the advanced therapy is of great importance for maximizing the benefit
Xinru Zhang, Gulizeba Aimaiti, Yuanye Guan, Yuzhe Sha, Wei Zhou, Jiefeng Shen, Bo Zhao, Wei‐En Yuan   +7 more
wiley   +1 more source

Integration of HIV Status in Cancer Surveillance in South Africa: A Call for Action

Cancer Medicine, Volume 15, Issue 3, March 2026.
ABSTRACT Background Human immunodeficiency virus (HIV) increases the risk of developing cancer. We aimed to assign HIV status to cancers diagnosed in public laboratories recorded in the National Cancer Registry (NCR) in South Africa, guided by HIV counselling and testing guidelines.
Carole Metekoua, Tracey Wiggill, Tinashe Tombe‐Nyahuma, Yann Ruffieux, Judith Mwansa‐Kambafwile, Stanford Kwenda, Tafadzwa G. Dhokotera, Julia Bohlius, Eliane Rohner, Mazvita Muchengeti   +9 more
wiley   +1 more source

Mechanistic role of GNE‐987 targeting BRD4‐HCP5 axis in pediatric T‐cell acute lymphoblastic leukemia

Journal of Cell Communication and Signaling, Volume 20, Issue 1, March 2026.
Abstract This study aims to explore the mechanism of action of the Bromodomain‐containing protein 4 (BRD4) inhibitor GNE‐987 in the treatment of pediatric T‐cell Acute Lymphoblastic Leukemia (T‐ALL), focusing on its effect in inhibiting T‐ALL cell proliferation by activating the HLA Complex P5 (HCP5) Super‐enhancer.
Xu Sang, Mengying Jiang, Yanchun Guan, Xin Chen, Zhen Zhang, Yumeng Wu, Wansheng Peng   +6 more
wiley   +1 more source

Transposable elements: Functional aspects and applications as drivers of crop innovation

Crop Science, Volume 66, Issue 2, March/April 2026.
Abstract Transposable elements (TEs), which were once relegated to the status of genomic parasites, are today accepted as important agents of plant genome evolution and adaptation. This review integrates evidence pointing to their dual function as drivers of genetic diversity and instability, with a focus on their contribution to phenotypic innovation,
Flávia Layse Belém Medeiros, José Ribamar Costa Ferreira‐Neto, Jarbson Henrique Oliveira Silva, Cinthia Carla Claudino Grangeiro Nunes, Ana Luíza Trajano Mangueira de Melo, Ayug Bezerra Lemos, Madson Allan de Luna‐Aragão, Agnes Angélica Guedes de Barros, Simon Orozco‐Arias, Eliseu Binneck, Francismar Correa Marcelino‐Guimarães, Ana Cristina Brasileiro‐Vidal, Ana Maria Benko‐Iseppon   +12 more
wiley   +1 more source

Signal Peptide Engineering and Codon Optimization to Enhance α‐Gal A Activity for rAAV Gene Therapy of Fabry Disease

Journal of Inherited Metabolic Disease, Volume 49, Issue 2, March 2026.
ABSTRACT Fabry disease is an X‐linked lysosomal storage disorder caused by mutations in the GLA gene, leading to deficient α‐galactosidase A (α‐Gal A) activity and pathological accumulation of globotriaosylceramide (Gb3) and globotriaosylsphingosine (Lyso‐Gb3) in various organs.
Siwu He, Li Yang, Ke Wan, Zhaoyue Zheng, Mi Leng, Chunmei Gan, Yu Liu, Lin Xiao, Jingya Ye, Zhian Chen, Jiao Zhou, C. Alexander Valencia, Aliah Abuammah, Hoi Yee Chow, Biao Dong, Yucheng Chen   +15 more
wiley   +1 more source

Heparanase, a host gene that potently restricts retrovirus transcription

mBio
Heparanase (HPSE) is a heterodimeric β-D-glucuronidase that is critical in mammalian cells for the enzymatic cleavage of membrane-associated heparan sulfate moieties.
Brandon Waxman, Kyle Salka, Uddhav Timilsina, Supawadee Umthong, Deepak Shukla, Spyridon Stavrou   +5 more
doaj   +1 more source

Regulatory evolution of innate immunity through co-option of endogenous retroviruses

Science, 2016
Edward B. Chuong, N. Elde, C. Feschotte
semanticscholar   +1 more source

Human Cyclophilins—An Emerging Class of Drug Targets

Medicinal Research Reviews, Volume 46, Issue 2, Page 475-512, March 2026.
ABSTRACT Cyclophilins are a family of enzymes with peptidyl‐prolyl isomerase activity found in all cells of all organisms. To date, 17 cyclophilin isoforms have been identified in the human body, participating in diverse biological processes. Consequently, cyclophilins have emerged as promising targets for drug development to address a wide array of ...
Katarina Jurkova, Hana Navratilova, Kamil Musilek, Ondrej Benek   +3 more
wiley   +1 more source